Agnieszka Tomala

Cracow University of Technology

About Presenter

Dr Tomala is a materials scientist and academic specialising in biotribology, surface engineering, and biomaterials for regenerative medicine, with a postdoctoral career characterised by leading international, interdisciplinary projects and strong industry collaboration. She is a recognised speaker and session chair at major forums, including the World Tribology Congress and the World Biomaterials Congress, and has held plenary roles at MMM 2025. Gold Medals at IPITEX 2025 and INTARG 2025, IWIS Gold 2021 and iENA Silver 2021 for bioactive composites. Since 2020, her research focus has shifted to titanium–hydroxyapatite composites functionalised by laser surface texturing and MXene coatings to extend implant lifespan and enhance osseointegration.

Title of presentation
Titanium–Hydroxyapatite Composites with MXene Coatings for Long-life, Osteoconductive Implants
Focus Areas

Next-Gen Therapies: From Lab to Life

Objective: See how biotech, AI and digital health are accelerating the future of medicine.

Introduction: the Problem

Load-bearing orthopaedic implants still fail due to fretting, wear debris, inflammation, and poor long-term osseointegration at the bone–implant interface, leading to costly, painful revision surgeries and reduced patient quality of life. The project develops a gradient biomaterial that combines cast titanium for toughness with an outer Titanium–hydroxyapatite (Ti/HAp) composite layer for osteoconductivity, further enhanced by laser surface texturing (LST) and 2D MXene coatings to simultaneously improve biointegration and biotribology. The scientific aims are to control HAp particle size, morphology, and content through powder metallurgy, create long-range ordered laser textures that increase porosity and guide cells, and embed Ti3C2Tx MXenes to form durable low-wear tribofilms—thus extending implant lifespan while enhancing cytocompatibility and osteoinduction.

Collaboration Offer

Seeking clinical, industrial, and translational partners to benchmark the Ti/HAp–LST–MXene system against current implant materials, co-develop preclinical protocols (tribology-in-synovial analogues, cytocompatibility/osteogenic markers, antimicrobial assays), and plan regulatory and scale-up pathways for device-relevant geometries. Collaboration options include: (a) co-design of indications and target use-cases (hip/knee stems, dental fixtures), (b) pilot manufacturing and coating transfer (airbrush MXene embedding into laser textures), and (c) predictive modelling (ML-guided texture geometry) to accelerate optimisation; partners gain early access to data, IP co-development opportunities, and visibility in joint dissemination. Expressions of interest are welcome from implant OEMs, coating/laser vendors, preclinical CROs, and clinical research units to assemble a commercialisation consortium and map a TRL 4→6 pathway.